"Two-year follow-up data on the efficacy and safety of KN026, a HER2-targeted bispecific antibody combined with docetaxel as first-line treatment for HER2-positive recurrent/metastatic breast cancer"
作者："Zhang, Q; Wang, J; Ouyang, Q; Wang, X; Lin, D; Wang, J; Gan, L; Ouyang, Z; Xu, T; Liu, Y; Lv, Y"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
作者："Zhou, C; Li, W; Song, Z; Zhang, Y; Zhang, Y; Huang, D; Yang, Z; Zhou, M; Mao, R; Huang, C; Li, X; Wang, J"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
The impact of cancer pain on survival of lung cancer patients receiving immune checkpoint inhibitors
作者："Wang, S; Ye, ZH; Zhang, J; Lee, TTL; Wai, AKC; Kong, F"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
作者："Ye, ZH; Wang, S; Zhang, J; Lee, TTL; Wai, AKC; Kong, F"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
A phase I dose escalation study of GCC19CART: A novel CoupledCAR therapy for subjects with metastatic colorectal cancer
作者："Cui, J; Chen, N; Pu, C; Zhao, L; Li, N; Wang, C; Huang, Y; Luo, S; Li, X; Yang, Z; Bie, J; Zhu, R; Tang, H; Liang, T; Wang, Y; Lu, V; Wu, Z; Song, Y; Xiao, L"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
作者："Wei, T"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
Hepatic arterial infusion chemotherapy (HAIC) combined with Regorafenib and PD-1 inhibitors versus Regorafenib combined with PD-1 inhibitors for second-line treatment Hepatocellular carcinoma (HCC)
作者："You, N; Peng, X; Li, J; Wang, L; Wu, K; Zheng, L; Li, D; Chen, Z; Zhang, H; Huang, P; Wang, Y; Liao, R; Li, Q; Guo, P; Wang, W"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/ TGF-bRII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors
作者："Xu, RH; Huiyan, L; Zhao, H; Wei, W; Ma, D; Yin, X; Ni, Y; Wang, Y; Zhang, Y; Zhou, J; Pan, H; Niu, Z; Zhang, J; Ren, H; Kang, M; Jia, W; Gu, S; Liu, P; Zhang, Z; Wang, S"
通讯作者：
来源出版物：ANNALS OF ONCOLOGY 卷：34 页：1 出版年：2023
文献类型：Meeting Abstract 影响因子：56.7 JCR分区：Q1 ESI学科分类：CLINICAL MEDICINE
TUG-891 inhibits neuronal endoplasmic reticulum stress and pyroptosis activation and protects neurons in a mouse model of intraventricular hemorrhage
作者："Wang, HX; Liu, C; Li, YY; Cao, Y; Zhao, L; Zhao, YJ; Deng, ZA; Tong, AP; Zhou, LX"
通讯作者："Tong, AP; Zhou, LX (通讯作者)，Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.; Tong, AP (通讯作者)，Sichuan Univ, West China Med Sch, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China."
来源出版物：NEURAL REGENERATION RESEARCH 卷：18 页：7 出版年：2023
文献类型：Article 影响因子：5.9 JCR分区：Q1 ESI学科分类：NEUROSCIENCE & BEHAVIOR
M2 macrophages mediate fibrotic scar formation in the early stages after cerebral ischemia in rats
作者："Huang, JG; Ren, JX; Chen, Y; Tian, MF; Zhou, L; Wen, J; Song, XS; Wu, YL; Yang, QH; Jiang, PR; Wang, JN; Yang, Q"
通讯作者："Yang, Q (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China."
来源出版物：NEURAL REGENERATION RESEARCH 卷：18 页：11 出版年：2023
文献类型：Article 影响因子：5.9 JCR分区：Q1 ESI学科分类：NEUROSCIENCE & BEHAVIOR
共39页
<<
<
2
3
4
5
6
7
8
9
10
11
>
>>
